Open AccessEvolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs
Author(s) -
Zohar Weinstein,
Muhammad H. Zaman
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01243-18
Subject(s) - mycobacterium smegmatis , mycobacterium tuberculosis , tuberculosis , microbiology and biotechnology , drug resistance , rifampicin , medicine , antibiotics , escherichia coli , biology , virology , genetics , pathology , gene
Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs. Rifampin resistance is a critical concern for tuberculosis treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom